Informed Consent Final Guidance: Drug Makers Get Some Tweaks But Not Every Change They Wanted
Executive Summary
From when the consent process starts to how to handle standard of care discussions, US FDA’s long-awaited final guidance on informed consent reflects some changes sought by sponsors. More changes may be in store soon due to revisions of the Common Rule.